Background: Treatment of superficial femoral artery (SFA) lesions remains challenging. We conducted a network meta-analysis of randomized controlled trials aiming to explore the efficacy of treatment modalities for SFA "de novo" lesions.
Peripheral arterial disease (PAD) is a substantial public health issue, affecting 15% to 20% of the population >75 years old. 1 Superficial femoral artery (SFA) occlusive disease is the most common cause of intermittent claudication of the calf. Owing to the fact that it has not been demonstrated which treatment modality alone or in combination may improve the results for the femoropopliteal sector, the search for the optimal therapeutic options has led to the development of new techniques and conduction of many studies in this era. A comprehensive standard of treatment guidelines for PAD was published by a multidisciplinary TransAtlantic
Inter-Society Consensus (TASC I) working group in the year 2000. 2 This report underscored a shift of treatment paradigm from conventional surgical revascularization to endovascular strategies for lower extremity arterial occlusive disease with therapeutic considerations based on disease pattern and morphologic stratification. With continuous advances in imaging equipment and endovascular technologies, minimally invasive techniques have become the mainstay treatment strategy for all types of femoropopliteal occlusive disease. Thus, updated treatment guidelines of the TASC II report were published in 2007, which further refined treatment guidelines based on morphologic stratification for aortoiliac and femoropopliteal occlusive disease. 3 During the past decade, several other endovascular revascularization strategies have been proposed, such as drugcoated balloon (DCB), angioplasty with optional bailout stenting, and primary stenting using a covered stent (CS) or drug-eluting stent (DES). However, it still remains unclear if these innovative techniques may result in better treatment outcomes that are clinically efficient. We conducted a systematic review of randomized controlled trials (RCTs) comparing the efficacy of treatment modalities in terms of primary patency and binary restenosis for SFA occlusive disease. With the intention of providing a clinically useful summary that can guide treatment decisions, we have comprehensively synthesized data by applying multiple-treatments meta-analysis (network meta-analysis). 4, 5 
METHODS

Search strategy
A combined computerized and manual systematic literature search in MEDLINE, Embase, Scopus, Google Scholar, Ovid, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov, proceedings of international congresses, and other relevant online material was performed, and reference lists were thereafter manually searched for relevant articles. Mesh terminology was used (Supplementary Methods, online only).
Eligibility criteria
A study was considered eligible for this meta-analysis if it:
1. Was an RCT. 2. Compared treatment modalities for femoropopliteal lesions causing either intermittent claudication or critical limb ischemia. Treatment modalities included femoropopliteal bypass surgery (BPS), balloon angioplasty (BA), nitinol stent (NS), stainless steel stent (SSS), CS, DES, DCB, cutting balloon (CB), percutaneous transluminal angioplasty with brachytherapy (PTABR), nitinol stent with cryoplasty (NSCR), and cryoplasty (CR) alone. 3. Provided data on outcome of interest for each group at follow-up of 12 months.
We excluded studies that did not refer to patients treated for PAD, did not report measures of efficacy for these treatment modalities, or were not RCTs.
Data extraction
Scientific papers published up to March 2016 were included without applying any language or other restrictions. We included all published RCTs on treatment modalities for de novo SFA lesions when inclusion criteria were met. If multiple publications of the same trial were retrieved or if there was a case mix between publications, only the most recent and informative publication was included. Two researchers (S.N.M., C.N.A.) independently extracted and analyzed the results of the systematic literature search using a specifically designed data collection pro forma that allowed a list of all relevant information. In case of discrepancies, the final decision was reached by consensus. We extracted characteristics of studies including study design, study duration, date of publication, total number of patients recruited, and treatment arms along with outcome measures of efficacy.
Outcome measures
The main outcome measures of this review were treated as dummy variables, reported in an intention-to-treat basis and referred to a 12-month follow-up period. These included 1. Primary patency, defined as nonoccluded treated arterial segment without any additional revascularization; and 2. Binary restenosis, defined as restenosis of the treated lesion with a 50% threshold according to reference vessel diameter by digital subtraction angiography, or a peak systolic velocity ratio $2.4, or absent flow indicating total occlusion by color duplex ultrasound evaluation.
The 12-month follow-up period was chosen as the most commonly reported follow-up period among the eligible RCTs. Statistical analyses were performed along with analysis of risk of bias and role of the funding source. A detailed description of the methodology followed can be found in the Supplementary Methods (online only).
Statistical analyses
Conventional meta-analysis for direct comparisons. A pooled estimate of odds ratios (ORs) together with the corresponding 95% confidence intervals (CIs) was calculated. A fixed-effects model (Peto method) or a random-effects model (Mantel-Haenszel method) was used for nonheterogeneous or heterogeneous data, respectively. Test for overall effect was applied (z-test), and statistical significance level was set to P < .05.
Network meta-analysis. Network meta-analysis (also known as mixed-treatments comparison or multipletreatments comparison meta-analysis) expands the scope of a conventional pairwise meta-analysis by analyzing simultaneously both direct comparisons of interventions within RCTs and indirect comparisons across trials based on a common comparator (eg, placebo or some standard treatment). In other words, network meta-analysis is a method to assess the comparative effectiveness of experimental treatment among similar populations of patients that have not been compared directly in an RCT. Unlike traditional meta-analyses, which summarize the results of trials that have evaluated the same treatment/placebo combination, network meta-analyses compare the results from two or more studies that have one treatment in common. Among the advantages of network metaanalysis compared with pairwise meta-analysis is the precision in the estimates and a concomitant output of a relative ranking of all treatments for the studied outcome. This is mainly achieved by the integration of direct evidence (from studies directly comparing interventions) with indirect evidence (information about two treatments derived by a common comparator) increases. The assumption of consistency (agreement between direct and indirect sources of evidence) underlies the methodology and can provide valuable information to patients, practitioners, and decision makers. We performed a network meta-analysis in a frequentist setting using multivariate meta-analysis to combine the different sources of evidence across a network of studies and to make inferences regarding the relative effectiveness of multiple interventions. We used the randomeffects model and assumed common heterogeneity across all comparisons. Guidelines from the International Society for Pharmacoeconomics and Outcomes Research-Academy of Managed Care Pharmacy-National Pharmaceutical Council Good Practice Task Force Report were followed. 6 The network meta-analysis allowed comparisons of treatment modalities that were not directly addressed within any of the individual trials. We performed the network framework to incorporate the indirect comparisons constructed from two trials that have one treatment in common (eg, a comparison of treatment "A vs C" with trials comparing "A vs B" and "B vs C"). As a result, we maintained the within-trial randomized treatment comparison of each trial while combining all available comparisons between treatments. The network meta-analysis produces tighter CIs than do other analyses, implying greater precision of the estimates. 7 We first plotted a network map to show which treatments are directly compared against which other treatments and to depict how much information is available for each treatment and for each treatment comparison. A network map is a graphical depiction of how each intervention is connected to the others through direct comparisons. Each line, or edge, depicts a direct comparison between two intervention nodes. The network meta-analysis derived summary treatment effects in terms of ORs with 95% CIs for each pair of treatments, and thereafter, the results were presented in the form of predictive interval plots, which are forest plots of the estimated summary effects along with their CIs for all possible comparisons, both direct and indirect. A funnel plot is a scatterplot of the study effect size vs some measure of its precision, often its inverted standard error. It is the most common tool used to assess the presence of small-study effects in a meta-analysis. We expanded its use and we constructed a "comparison-adjusted" funnel plot to assess the presence of small-study effects and to assess the presence of heterogeneity and bias (including publication bias) in the network metaanalysis. In this type of plot, treatments should be named in an order that represents a characteristic potentially associated with small-study effects. In our case, comparisons have been defined with a consistent direction (newer vs older treatment modalities). Inconsistency refers to differences between direct and various indirect effect estimates for the same comparison. Important inconsistency threatens the validity of the results and, if present, needs further exploration to identify possible sources of disagreement. Consistency of the RCTs included in the network was checked by applying inconsistency and node-splitting models, with corresponding z-tests. A P value > .05 for inconsistency factors or the comparison between direct and indirect effects in the node-splitting analysis indicated a lack of significant inconsistency. To examine the comparative efficacy among the 11 treatment modalities, we used results of network meta-analysis taking primary patency as positive and binary restenosis as negative outcome. We expressed these using BA as the reference modality because it has been consistently used as the reference treatment among the different pairwise comparisons among most of the eligible studies and because of the fact that network meta-analysis methodology imposes the most common category as a reference. We estimated the ranking probability for each treatment modality, that is, the most efficacious or the best regimen, the second best, the third best, and so on. We used the surface under the cumulative ranking curve (SUCRA) plots as a reliable and comprehensive graphical way to present ranking efficacy probabilities and their uncertainty. The SUCRA is a plot used to provide a hierarchy of the treatments and accounts for both the location and the variance of all relative treatment effects. SUCRAs express the percentage of effectiveness of a treatment that would be ranked always first without any uncertainty. SUCRAs are not probabilities. Their advantage over probability of being best is that they take into account the entire distribution of the ranking probabilities. The larger the SUCRA value, the better the rank of the treatment. We considered SUCRA ¼ 100 if a treatment modality always ranks first and 0 if it always ranks last. We also used unique dimension estimated from multidimensional scaling (MDS) plots to rank the competing treatments. MDS is an alternative approach to rank the competing treatments and to represent them spatially or geometrically, preferably on a system of coordinate axes. The results of both ranking approaches (SUCRA and MDS) were used to produce clusters of treatments for the two studied outcomes (primary patency and binary restenosis) and were presented as clustered ranking plots. Cluster analysis is a common exploratory data mining technique for grouping objects based on their features so that the degree of association is high between members of the same group and low between members of different groups. There are differences between SUCRA and MDS ranking; however, the differences pertain only to the treatments that are close in rank. Finally, we explored the influence of population and design characteristics on the effect estimates of our network by conducting a meta-regression analysis. In meta-regression, the outcome variable is the effect estimate (in our case, log OR), whereas the explanatory variables are characteristics of studies that might influence the size of intervention effect. These are often called potential effect modifiers or covariates. Results of metaregression analysis test whether there is a relationship between intervention effect and the explanatory variable. Exchangeability-transitivity assumption is a fundamental assumption of network meta-analysis, and if it is violated, results would be invalid. 4 We fulfilled the transitivity assumption by (1) conceptual analysis (we evidenced that eligible treatments were "jointly randomizable" because of no significant differences in baseline patients' characteristics) and (2) statistical analysis (by comparing the distribution of prespecified potential effect modifiers across the direct comparisons and by using observed event rate in the reference arm as baseline-risk adjustment approach). A detailed glossary and explanations about the network meta-analysis terminology are provided by Cochrane in http://cmim.cochrane.org/glossary. All analyses were conducted using Stata Statistical Software, release 13 (StataCorp, College Station, Tex).
RESULTS
As shown in the flow diagram ( Supplementary Fig 1,  online only) , 196 studies were deemed potentially eligible of 3917 analyzed studies. Of these, 163 studies were excluded on the basis of exclusion criteria. Finally, 33 studies were deemed eligible (Supplementary Tables I  and II , online only), none of which was performed on mutually overlapping populations, including a total of 66 study arms and evaluating 4659 patients. All trials were two-armed RCTs. The mean study duration of all the studies was 31.0 6 12.2 months. Characteristics of the eligible studies are shown in Table I . Analysis of the risk of bias of eligible trials, reporting of methodologic quality with allocation concealment, and blinding of outcome assessment according to the Cochrane Collaboration tool are shown in Supplementary Table III (online  only) . All eligible trials were of generally high quality.
Results of conventional meta-analysis on primary patency and binary restenosis are presented in the Supplementary Results (online only) and Table II .
Network meta-analysis Primary patency. A total of 9 treatment modalities in 19 eligible studies (Supplementary Table I , online only) evaluating primary patency in patients treated for femoropopliteal arterial disease were used in the network (Fig 1) . Results of the network meta-analysis are presented in Fig 2 Comparison of SSS with DCB yielded a significant result (OR, 0.34; 95% CI, 0.12-0.99). Last, significantly different primary patency rates were also recorded when SSS was compared with DES (OR, 0.08; 95% CI, 0.02-0.31) and when SSS was compared with NS (OR, 0.28; 95% CI, 0.10-0.78). A result of borderline significance was recorded when NS was compared with DES (OR, 0.28; 95% CI, 0.08-1.05). No significant or borderline differences were identified in the rest of the potential pairwise comparisons.
The comparison-adjusted funnel plot for primary patency during 12 months is shown in Supplementary  Fig 2 (online only) . The plot suggested that there was no association between the study size and its effect. Furthermore, evaluation of inconsistency using loopspecific heterogeneity estimates found one quadratic Supplementary Fig 3 (online only 
Our analysis for ranking of treatments based on the probability for each treatment's being the best indicated that DES was most probable to be rank 1 (64.6%), BPS to be rank 2 (49.7%), CS to be rank 3 (40.5%), NS to be rank 4 (39.4%), DCB to be rank 5 (34.2%), PTABR to be rank 6 (28.6%), BA to be rank 7 (55.5%), SSS to be rank 8 (34.8%), and CR to be rank 9 (54.6%).
Binary restenosis. Binary restenosis in patients treated for femoropopliteal arterial disease was evaluated by 9 treatment modalities in 20 eligible studies (Supplementary Table II The comparison-adjusted funnel plot for binary restenosis during 12 months (Supplementary Fig 4, online only) suggested that there was no association between the study size and its effect, whereas evaluation of inconsistency using loop-specific heterogeneity estimates found no triangular or quadratic loops. Node-splitting approach did not yield significant results (all P values > .97). Our analysis for ranking of treatments based on the probability for each treatment's being the best showed that NSCR was most probable to be rank 1 (63.2%), DCB to be rank 2 (38.5%), CS to be rank 3 (30.8%), CB to be rank 4 (14.1%), NS to be rank 5 (40.0%), PTABR to be rank 6 (32.2%), BA to be rank 7 (58.6%), SSS to be rank 8 (55.9%), and CR to be rank 9 (95.6%) in terms of treatment efficacy, evaluated by binary restenosis network.
The results of both SUCRA and MDS were used to produce clusters of treatments for the two studied outcomes, primary patency and binary restenosis (Fig 7,  a and b, respectively) . Optimal number of clusters was equal to 3 for SUCRA analysis and equal to 2 for MDS analysis. As a result, order of treatments (ranked from best to worst) included CS, NS, DCB, PTABR (group 1), BA, SSS (group 2), and CR (group 3).
Our metaregression analysis did not evidence statistically significant influence of potential modifiers, namely, mean lesion length, patients with Rutherford classification stage $4, mean age, event rates in reference group, and percentage of male study participants. Year of publication was used as a proxy of the evolution of treatment modalities during the study period. Again, no statistically significant results were found (Supplementary Table VI, online only).
DISCUSSION
This network meta-analysis indicated significant differences among different treatment modalities for SFA de novo lesions. In terms of primary patency, DES had the greatest likelihood of being the most effective treatment at 12 months of follow-up. DES combined the benefit of NS, which was designed to accommodate the severe stresses encountered in the SFA, including angulations, rotation, and longitudinal compression, and the local delivery of drugs, which inhibit cell proliferation and the resultant restenosis. 8, 9 It should, however, be distinguished that the length of the drug delivery widely varies between drug-eluting and drug-coated stents. Initial studies of DES for SFA lesions were hampered by lack of clinical benefit. 10, 11 However, evolution in DES technology has addressed significant pharmacokinetic issues that constituted the "Achilles heel" in early studies, such as underdosing of the delivered drug and inadequate drug elution kinetics. In the Zilver PTX study, the selfexpanding NS with 3 mg/mm 2 polymer-free paclitaxel coating on its outer surfaces showed significant benefit for the SFA lesions compared with both BA and placement of a bare nitinol self-expanding stent. 12 As a result, DES therapy may offer a promising strategy for treating SFA lesions. A second interesting finding of our review was that BPS ranked second in the network of studies evaluating primary patency, close to DES. BPS has been a mainstay in the invasive treatment of femoropopliteal occlusive disease for five decades. Our finding may indicate that BPS still retains its role as a principal intervention. This can be justified by the fact that BPS is usually performed in patients with advanced SFA disease and especially in heavily calcified lesions, longer segment disease, and total occlusions. 13 Our analysis indicated that CS and NS were ranked third and fourth, depending on the outcome evaluated. The theoretical benefit of the expanded CS is the prevention of in-stent growth of tissue between the stent struts, which plagues SFA stents.
14 However, edge restenosis and concerns about stent thrombosis are two important issues that have not yet been addressed. 15 Although the first generation of NS demonstrated a relatively high rate of fractures, 10, 16 advances in technology introduced a second generation of NS with improved conformability, greater radial strength, and lower rates of long-term stent fracture. 17 Nevertheless, even with the new generation of NS, the restenosis rate is still considerable, especially for longer stented segments. 17 Furthermore,
another clinically important finding of our review was that all treatment modalities demonstrated superiority over BA in terms of primary patency. Initial flowlimiting dissection and elastic recoil as well as delayed neointimal hyperplasia after BA can justify this negative finding.
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The second important end point investigated in our study was the binary stenosis at 12 months. An interesting finding of our analysis was that combination of NS and CR and DCB were the two most probably effective treatments. Owing to the fact that NS with CR was the only combination therapy identified in the RCTs so far, it should be further explored whether combination therapies are more promising than monotherapies. The use of DCB may be an effective alternative to DES, as any stentless technology for the improvement of long-term patency might be preferable to the longterm presence of a foreign body. The local delivery of drugs that inhibit cell proliferation can justify the low recurrence of restenosis. 8 On the contrary, potential drawbacks may include elastic recoil and the occurrence of flow-limiting dissection, as very calcific stenosis or total occlusions are commonly found in the femoropopliteal vessels. In a recent meta-analysis of RCTs on paclitaxelcoated balloons by Katsanos et al, 19 stent presence was found to be positively correlated with reduced late lumen loss. This finding may justify why DCB showed better results concerning restenosis compared with CS and NS but also a lack in patency rate in comparison to CS and NS. Two clusters of treatment rankings were identified when we investigated the efficacy of the treatment options by combining the outcome measures of primary patency and binary restenosis. The first was characterized as high-performance cluster and included CS, NS, DCB, and PTABR; the second was characterized as low-performance cluster and included BA and SSS. Strikingly, it seems that modern endovascular techniques may provide improved outcomes for patients with de novo femoropopliteal arterial lesions compared with more dated treatment modalities like BA and SSS. Our analysis evidenced that CR could either be included in the low-performance cluster or form a third, even lower in performance cluster, depending on the analysis method followed. Although some authors have supported that CR is a more uniform and less traumatic procedure 9 and with reduced elastic recoil induction of cell apoptosis, which produces less intimal hyperplasia, currently even the most enthusiastic supporters of the method have reconsidered their initial results. 20 As a result, the efficacy of CR alone cannot be established, there are insufficient data to support its routine use, and its future role in the treatment of PAD should be cautiously investigated. Debulking procedures alone or in combination with other treatment modalities may confer superior primary patency after revascularization. Four different atherectomy device types are available for use: directional, rotational, orbital (or 360-degree), and excimer laser. The risk of debris embolization to the distal vasculature exists, however; thus, the use of an embolic protection device is recommended. Unfortunately, the currently available data on the different types of atherectomy for the treatment of de novo lesion of the SFA are obtained only by single-arm studies and registries and as such could not be included in our network meta-analysis. 21, 22 The relatively small number of studies assessing a particular pair of treatments for SFA lesions makes direct comparisons inevitably limited. Results of conventional meta-analysis evidenced that BPS, DCB, DES, and NS performed better in terms of primary patency compared with BA. Concerning binary restenosis, DCB, NS, PTABR, and NSCR were more efficient than BA. These results were also replicated on the network. However, no ranking or comparison among all available modalities can be reported from conventional meta-analysis. Our analysis, encompassing probabilistic model analysis, has the strength of producing indirect comparisons and allows data synthesis that can help identify the most effective treatment. Even when results of the direct evidence are conclusive, combining them with results of similar indirect estimates in a mixed-treatment comparison may yield a more precise estimate for the interventions directly compared. 6 Our study has confirmed the results of a previous meta-analysis by Katsanos et al comparing different endovascular options for occlusive disease in the femoropopliteal artery, which concluded that paclitaxel-eluting stents and paclitaxel-coated balloons offer the best longterm results. 19 However, the latter study did not include comparisons with BPS and other endovascular options, such as CB and SSS. Furthermore, among the strengths of our systematic review was that we evaluated a total of 11 different treatment modalities, incorporating all current evidence from generally high-quality RCTs, as evidenced by the Cochrane Collaboration tool, including 66 study arms and evaluating 4659 patients. We focused on two main clinical outcomes (primary patency and binary restenosis) that are considered clinically meaningful for evaluating the SFA treatment options. We chose to include data from RCTs pertaining to 12 months for reasons of homogeneity and as this was the most common follow-up period among the eligible studies. Although it is possible that low power might have occurred, our metaregression analysis did not capture significant effect of potential modifiers, namely, mean lesion length, disease severity, age, gender, and publication year, on pooled effect estimates. Potential limitations of our study may include heterogeneity among the eligible studies. For the primary patency, we did not find loops to be inconsistent; whereas for binary restenosis, the loop-specific approach could not be performed because there were no loops. Although tests for inconsistency have low power and may fail to detect inconsistency even when it is present, in our case, the studies were deemed sufficiently similar across comparisons, and metaregression analysis did not find important modifiers. Our analysis pointed toward the exchangeability-transitivity among the eligible studies; this provided support for our assumption of consistency. A potential bias may also occur in association with the small number of two-armed studies identified (19 for primary patency and 20 for binary restenosis network) so far in the literature. Furthermore, we had to exclude trials that did not report outcomes of primary patency or binary restenosis or because they did not report outcomes on 12 months. However, this may strengthen the purpose of conducting a network metaanalysis as the conventional meta-analyses are limited by their ability to access only the evidence from direct comparisons between two treatments and network is the optimal analysis for maximizing the information that can be extracted from all available current data. Most of the included RCTs were recognized as having low risk of bias as evidenced by the Cochrane Collaboration tool, which evaluates the quality of an RCT in several levels. However, the impact of industry sponsorship could not be evaluated because of limited reporting reasons. Furthermore, despite the increasing number of patients treated for the knee lesions, the total number of studies and patients randomly assigned to the eligible RCTs is probably still small. This may indicate specific difficulties associated with increased cost of newer treatment modalities. The results of the current study apply only to de novo lesions and do not inform the clinically important issue of which treatment modality is the best option for recurrent lesions. Furthermore, no published RCT including a medical arm with the above-mentioned end points was detected after applying our inclusion criteria, and as a result, the efficacy of the medical treatment of SFA lesions could not be evaluated. However, even though a study with a medical arm was detected, insufficient statistical power would probably jeopardize the robustness of the results.
Our results should be interpreted on the basis that primary patency and binary restenosis of the treated lesion were considered. Although we presented ranking of treatments based on the probability of being the best for each treatment, interpretation of the results based solely on this approach should be avoided because of potential uncertainty in the relative treatment effects, which can give higher ranks to treatments with scarce evidence. For this reason, we also employed SUCRA and MDS values. Clinical outcome of the patients as described by mortality, adverse event rates, and quality of life changes could be potential end points for future network studies. However, we could not "network" analyze such outcomes because of scarce data of the eligible studies; notwithstanding, it can be reasonable to assume that the applied outcomes of primary patency and binary restenosis can provide an estimation of the clinical efficacy of the investigated treatment options. In addition, interventions that are most effective in the intermediate phase of 12 months might not be the best choice for long-term treatment of the knee lesions. What is more, potential modifiers, such as peak flow velocity on duplex ultrasound, were probably defined differently in some of the eligible studies, which might be a potential source of bias. However, this issue could not be addressed as not all studies reported quantitative data. The latter was also the consequence of scarcity of separate data for patients with intermittent claudication and critical limb ischemia. Last, no data regarding binary restenosis after DES or BPS and no data regarding primary patency after CB were described in the RCTs included in our network meta-analysis. As a result, these modalities cannot be evaluated in the composite outcome of primary patency and binary restenosis.
CONCLUSIONS
According to our network meta-analysis, DES and BPS showed the best primary patency rates at 12 months of follow-up, followed by CS, NS, and DCB, for SFA de novo lesions. DES has shown encouraging results; however, its long-term safety and efficacy have yet to be proven in a sufficiently broader range of patient types and a wider range of arterial lesions. Moreover, BPS still maintains its proven role as a first-line intervention, whereas BA, SSS, and CR appear to be less effective treatment options for SFA occlusive disease. These results may have potential clinical implications that should be considered in the development of clinical practice guidelines or the design of future RCTs.
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APPENDIX (online only).
Supplementary background data Special characteristics of superficial femoral artery (SFA). Several factors may influence the clinical outcome after SFA interventions. In particular, the anatomic territory of the SFA represents the most challenging vascular region in the body for catheter-based interventions. The SFA is the longest artery in the arterial circulation with the fewest side branches, and it is fixed between two major flexion joints, the hip and the knee. Multiple geometric forces are exerted on the SFA during routine movements. These forces include longitudinal and lateral compression, flexion, elongation, and torsion. In addition, the distal segment of the artery traverses a narrow canal, the adductor or Hunter canal, marked by the junction of aponeurosis of the vastus medialis, the adductor longus, and the sartorius muscle. This anatomic canal exerts further external compression on the SFA during exercise partly owing to thigh muscle contraction. As a result, treatment of SFA disease remains challenging because of complex lesion morphologies, unique vessel characteristics, long lesion lengths, and frequent chronic total occlusions, whereas the optimal therapeutic strategies remain a subject of debate. 1 
Supplementary methods
PRISMA guidelines followed. We used the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines, 2 the recent extension of the PRISMA statement for network meta-analysis, 3 and standard guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions (version 5. Assessment of risk of bias. Systematic reviews should carefully consider the potential limitations of the studies included. The quality of the included randomized controlled studies was evaluated with the Cochrane Collaboration's tool for assessing risk of bias. 4 This tool separates a judgment about risk of bias from a description of the support for that judgment, for a series of items covering different domains of bias (ie, selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias). In particular, the bias risk of trials was assessed taking into account (1) sequence generation of the allocation, (2) allocation concealment, (3) blinding of participants, personnel, and outcome assessors, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other sources of bias.
Role of the funding source. No commercial company was involved in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the report for publication. All authors approved the final version of the manuscript.
Supplementary results
Conventional meta-analysis. Results of conventional meta-analysis on primary patency and binary restenosis are presented in Table II Results on conduit type and indications for femoropopliteal bypass surgery patients among the eligible studies. In the study by Kedora et al comparing the effectiveness of treating SFA occlusive disease percutaneously with expanded polytetrafluoroethylene (ePTFE)/ nitinol self-expanding stent grafts vs surgical femoralto-above knee popliteal artery bypass, a synthetic graft material (ePTFE or Dacron) was used. Among the 50 patients enrolled in the bypass group, 19 (38%) were clinically classified into Rutherford stage $4. In the study by Lepäntalo et al comparing endoluminal PTFE thrupass with surgical bypass (a femoropopliteal bypass), a noncoated ePTFE graft above the knee was used. No major differences regarding clinical indication (percentage of critical limb ischemia [CLI] patients in each group) or extent of the lesion (mean lesion length, 10.3 vs 12.6 cm) were identified. Among the 21 patients who received a femoropopliteal bypass, two (9%) had CLI. Finally, in the study by van der Zaag et al comparing BA vs surgical bypass, an in situ or reversed autogenous vein above-the-knee graft was used. Baseline characteristics (clinical indication, mean length) were similar for both treatment groups. None of the 25 patients who received a bypass had CLI (Rutherford stage $4). The included studies found no statistical difference in terms of clinical 245.e1 Antonopoulos et al
Journal of Vascular Surgery
indication or extent of the lesion between surgical and interventional arms. Supplementary Fig 4 ( Supplementary 
